Core Center

风湿病的诊断、发病机制、监测疾病活动和新的治疗方法是以患者为导向的生物医学研究，这是约翰霍普金斯风湿病分部的标志。这项研究围绕硬皮病(弗雷德·威格利博士)、狼疮(米歇尔·佩里博士)、关节炎(琼·巴顿博士)和脉管炎(约翰·斯通博士)等著名疾病卓越中心展开。这些临床队列与安东尼·罗森博士和利维亚·卡西奥拉·罗森博士指导的强大的基础科学计划密切结合在一起。近年来，该计划得到了杰出的机构支持，实现了显著增长，在共享设备和基础设施方面进行了投资，并在事业部内外启动了多个协同项目。我们的风湿病研究核心中心(RDRCC)计划利用了风湿病学部强大的生物医学研究基础，以及约翰·霍普金斯大学更广泛的科学界的更多杰出人才。 霍普金斯RDRCC提案包括一个由Antony Rosen博士和John Stone博士领导的行政核心(核心A)，并包括两个科学核心：1)一个生物化验核心(核心B)，由詹姆斯·马奥尼、Mark Soloski和Livia Casciola-Rosen博士领导；以及2)一个基因分型/基因组学核心(核心C)，由凯瑟琳·巴恩斯博士领导，旨在促进该部门疾病中心内外的新研究。核心A将通过核心促进跨学科研究，提供财务管理方面的援助，提供信息技术解决方案，以最大限度地提高翻译研究的效率，并协调项目充实活动。行政核心还将管理试点和可行性方案。第一年选择的试点研究与疾病中心和核心密切相关。Pilot#1将优化分析，以量化直接在体外清除儿童SLE患者中的凋亡细胞。实验#2将探索颗粒酶B的遗传多态与硬皮病的特殊表型之间的关系。Core B将在患者样本的获取、处理、存储和分配方面提供帮助，并提供多种免疫分析，包括流式细胞仪、酶联免疫吸附试验、免疫组织学和多种细胞因子分析。Core C将在各种人类疾病和对照组织以及一些小鼠模型中进行、分析和解释基因表达研究。Core C还将监督明确定义的人类风湿性表型的遗传关联研究的设计、执行和分析。

Patient-oriented biomedical investigation related to diagnosis, disease mechanisms, monitoring disease activity and new therapeutic approaches in rheumatic disease is the hallmark of the Johns Hopkins Division of Rheumatology. This research is structured around well-established disease-specific Centers of Excellence in scleroderma (Dr. Fred Wigley), lupus (Dr. Michelle Petri), arthritis (Dr. Joan Bathon), and vasculitis (Dr. John Stone). These clinical cohorts are coupled closely with a robust basic science program directed by Drs. Antony Rosen and Livia Casciola-Rosen. In recent years, this program has received outstanding institutional support, enabling significant growth, investment in shared equipment and infrastructure, and the initiation of multiple synergistic projects both within and outside the Division. Our Rheumatic Disease Research Core Center (RDRCC) proposal capitalizes upon the strong biomedical research base within the Division of Rheumatology, as well as additional outstanding talent from the broader scientific community at Johns Hopkins. The Hopkins RDRCC proposal comprises an Administrative Core (Core A) led by Drs. Antony Rosen and John Stone, and includes 2 Scientific Cores: 1) a Bioassay Core (Core B), led by Drs. James Mahoney, Mark Soloski, and Livia Casciola-Rosen; and 2) a Genotyping/Genomics Core (Core C), led by Dr. Kathleen Barnes, designed to foster new research within and beyond the Division's Disease Centers. Core A will promote interdisciplinary research through the cores, provide assistance with financial management, provide information technology solutions to maximize efficiency of translational research, and coordinate program enrichment activities. The Administrative core will also manage the Pilot and Feasibility program. Pilot studies chosen for the first year are tightly linked to the disease Centers and Cores. Pilot #1 will optimize assays to quantify clearance of apoptotic cells directly ex vivo in pediatric SLE patients. Pilot #2 will explore the association of genetic polymorphisms in granzyme B with specific phenotypes in scleroderma. Core B will provide assistance with patient sample acquisition, processing, storage, and distribution, as well as the provision of multiple immunological assays, including FACS, ELISA, immunohistology, and multiplex cytokine assays. Core C will perform, analyze, and interpret gene expression studies in a variety of human disease and control tissues and some mouse models. Core C will also oversee the design, performance and analysis of genetic association studies in well-defined human rheumatic phenotypes.